This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MMV 253, MMV-253, AZ13721412, AZ-13721412
MMV253 is an investigational antimalarial compound discovered by MMV and AstraZeneca, India. MMV253 belongs to a novel class of anti-malaria drugs known as triaminopyrimidines (TAPs). With a predicted half-life of 36 hours in humans, TAPs offer the potential for single dose cure in combination with suitable partner drugs. The predicted dose to give coverage above Minimal Parasiticidal Concentration for over 8 days is 500mg. MMV253 rapidly kills parasites across all intra-erythrocytic stages and is active against multiple strains of plasmodium falciparum resistant to currently available anti-malarials as well as novel anti-malarials in clinical development. MMV253 may target the V-type H+ ATPase as selection for resistance results in mutations in the vacuolar ATP-synthase subunit D.
MMV and Zydus
In September 2016, MMV and Zydus Cadila have announced a collaboration to develop the investigational antimalarial compound MMV253. Zydus will lead development of the novel compound, and MMV will provide support.
Partners: Medicines for Malaria Venture AstraZeneca PLC
Additional information available to subscribers only: